Compare XBP & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBP | TCRX |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.3M | 49.4M |
| IPO Year | 2021 | 2021 |
| Metric | XBP | TCRX |
|---|---|---|
| Price | $2.89 | $0.19 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 5.0K | ★ 573.2K |
| Earning Date | 11-13-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 183.67 | 12.28 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $872,690,000.00 | $10,325,000.00 |
| Revenue This Year | $2.47 | N/A |
| Revenue Next Year | $10.86 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $0.41 | $0.18 |
| 52 Week High | $8.55 | $1.97 |
| Indicator | XBP | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.62 | 28.41 |
| Support Level | $2.76 | N/A |
| Resistance Level | $3.00 | $0.37 |
| Average True Range (ATR) | 0.18 | 0.02 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 46.64 | 20.75 |
XBP Global Holdings Inc is a multinational technology and services company that drives intelligent workflows for organizations. Through its proprietary platforms, agentic AI-driven automation, and domain expertise across industries and the public and private sectors, the firm enables its clients to entrust their digital transformations and workflows. The segments of the company are Applied Workflow Automation and Technology. The Applied Workflow Automation segment generates maximum revenue and provides services powered by intelligent, AI-enabled workflows that generate outcomes for client's systems, while the Technology segment focuses on the sale of recurring and perpetual software licenses, software maintenance and professional services, as well as hardware solutions and maintenance.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.